Search results for: Monoclonal Anti-dEGF Receptor, Cytoplasmic Domain produced in mouse Antibody
#29708866 // To Up
The Characterization of Monoclonal Antibodies to Mouse TLT-1 Suggests That TLT-1 Plays a Role in Wound Healing.Platelets play a vital role in hemostasis and inflammation. The membrane receptor TREM-like transcript-1 (TLT-1) is involved in platelet aggregation, bleeding, and inflammation, and it is localized in the Î±-granules of platelets. Upon platelet activation, TLT-1 is released from Î±-granules both in its transmembrane form and as a soluble fragment (sTLT-1). Higher levels of sTLT-1 have been detected in the plasma of patients with acute inflammation or sepsis, suggesting an important role for TLT-1 during inflammation. However, the roles of TLT-1 in hemostasis and inflammation are not well understood. We are developing the mouse model of TLT-1 to mechanistically test clinical associations of TLT-1 in health and disease. To facilitate our studies, monoclonal murine TLT-1 (mTLT-1) antibodies were produced by the immunization of a rabbit using the negatively charged region of the mTLT-1 extracellular domain PPVPGPREGEEAEDEK. In the present study, we demonstrate that two selected clones, 4.6 and 4.8, are suitable for the detection of mTLT-1 by western blot, immunoprecipitation, immunofluorescent staining, flow cytometry and inhibit platelet aggregation in aggregometry assays. In addition, we found that the topical administration of clone 4.8 delayed the wound healing process in an experimental burn model. These results suggest that TLT-1 plays an important role in wound healing and because both clones specifically detect mTLT-1, they are suitable to further develop TLT-1 based models of inflammation and hemostasis in vivo.
Barbara Manfredi, Jessica Morales-OrtÃz, Lymarie M DÃaz-DÃaz, Liz Hernandez-Matias, Delmaliz Barreto-VÃ¡zquez, Javier MenÃ©ndez-PÃ©rez, J Alejandro RodrÃguez-Cordero, Juan C Villalobos-Santos, Edgardo Santiago-Rivera, Adriana Rivera-Dompenciel, Eunice L Lozada-Delgado, Madhavi Kuchibhotla, Kelvin Carrasquillo-CarriÃ³n, Abiel Roche-Lima, A Valance Washington
1411 related Products with: The Characterization of Monoclonal Antibodies to Mouse TLT-1 Suggests That TLT-1 Plays a Role in Wound Healing.100.00 ug100ug100 ug100ug100ul100ug100ug100ug Lyophilized100ug Lyophilized100.00 ug100ug100ug
#27987190 2016/12/16 To Up
Domain-Specific Monoclonal Antibodies Against Human Rev-erbÎ².The nuclear receptor Rev-erbÎ² is a potent transcriptional factor whose functional study has been limited by the lack of suitable antibodies against it. To better understand Rev-erbÎ²'s biological roles, we generated five hybridoma cell lines secreting antibodies against human Rev-erbÎ² in mice immunized with the purified, prokaryotically expressed recombinant Rev-erbÎ²-6His fusion protein. Using Western blotting and immunofluorescence analyses, all the five monoclonal antibodies (MAbs) showed strong immunoreactivity to both prokaryotically and eukaryotically expressed recombinant Rev-erbÎ². An immunoprecipitation study showed that all five monoclonal antibodies against Rev-erbÎ² were able to pull down the recombinant Rev-erbÎ²-Flag protein, but only one of the MAbs against Rev-erbÎ², 37H8, could pull down the endogenous Rev-erbÎ² protein. Furthermore, domain specificity of these MAbs was characterized. Due to the high similarities between Rev-erbÎ± and Rev-erbÎ² in the C and E domains, those C and E domain-specific anti-Rev-erbÎ² antibodies can react with human Rev-erbÎ± as well. The MAbs produced in the study will provide a valuable tool for investigating the function of Rev-erbÎ².
Fang Chen, Yanqing Li, Junli Zhao, Qinwen Mao, Haibin Xia25 µg4 Membranes/Box0.1 ml4 Membranes/Box1 mg4 Arrays/Slide4 Arrays/Slide4 Membranes/Box1 mg100.00 ug
#23575465 2013/04/10 To Up
Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.Sialoadhesin (Sn)-expressing monocytes/macrophages have been associated with several diseases like inflammatory and autoimmune disorders as well as viral infections, and they also appear to play a role in the initiation of an adaptive immune response. This makes Sn-expressing cells not only attractive targets for cell-directed therapies, but also an appealing target for vaccination. Furthermore, since Sn was shown to be an endocytic receptor, the conjugation of effector molecules to an Sn-specific ligand should allow intracellular delivery of these conjugates. Previously, we developed functional Sn-specific immunoconjugates that were generated via chemical coupling. Although successful, the system requires significant optimization for each immunoconjugate to be made. To generate a more flexible and controlled system, we developed a recombinant antibody vector allowing the creation of genetic antibody fusion constructs. This paper reports on the characterization of the recombinant antibody and the evaluation of its use for Sn-directed targeting.
Karen Ooms, Hanne Van Gorp, Tim Van Gaever, Hans J Nauwynck, Peter L Delputte
2470 related Products with: Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.1mg51 module1 module100ug/vial1 module1 module1 module1 module1 module1 module1 module
#22069720 2011/05/13 To Up
Botulinum neurotoxins and botulism: a novel therapeutic approach.Specific treatment is not available for human botulism. Current remedial mainstay is the passive administration of polyclonal antibody to botulinum neurotoxin (BoNT) derived from heterologous species (immunized animal or mouse hybridoma) together with supportive and symptomatic management. The antibody works extracellularly, probably by blocking the binding of receptor binding (R) domain to the neuronal receptors; thus inhibiting cellular entry of the holo-BoNT. The antibody cannot neutralize the intracellular toxin. Moreover, a conventional antibody with relatively large molecular size (150 kDa) is not accessible to the enzymatic groove and, thus, cannot directly inhibit the BoNT zinc metalloprotease activity. Recently, a 15-20 kDa single domain antibody (V(H)H) that binds specifically to light chain of BoNT serotype A was produced from a humanized-camel VH/V(H)H phage display library. The V(H)H has high sequence homology (>80%) to the human VH and could block the enzymatic activity of the BoNT. Molecular docking revealed not only the interface binding between the V(H)H and the toxin but also an insertion of the V(H)H CDR3 into the toxin enzymatic pocket. It is envisaged that, by molecular linking the V(H)H to a cell penetrating peptide (CPP), the CPP-V(H)H fusion protein would be able to traverse the hydrophobic cell membrane into the cytoplasm and inhibit the intracellular BoNT. This presents a novel and safe immunotherapeutic strategy for botulism by using a cell penetrating, humanized-single domain antibody that inhibits the BoNT by means of a direct blockade of the groove of the menace enzyme.
Jeeraphong Thanongsaksrikul, Wanpen Chaicumpa25 mg1 mg1000 tests100ul50 ug 200ul1 ml100 mg1 mg10 mg
#21987375 // To Up
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).Osteoclasts (OC) are bone-resorbing, multinucleated cells that are generated via fusion of OC precursors (OCP). The frequency of OCP is elevated in patients with erosive inflammatory arthritis and metabolic bone diseases. Although many cytokines and cell surface receptors are known to participate in osteoclastogenesis, the molecular mechanisms underlying the regulation of this cellular transformation are poorly understood. Herein, we focused our studies on the dendritic cell-specific transmembrane protein (DC-STAMP), a seven-pass transmembrane receptor-like protein known to be essential for cell-to-cell fusion during osteoclastogenesis. We identified an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail of DC-STAMP, and developed an anti-DC-STAMP monoclonal antibody 1A2 that detected DC-STAMP expression on human tumor giant cells, blocked OC formation in vitro, and distinguished four patterns of human PBMC with a positive correlation to OC potential. In freshly isolated monocytes, DC-STAMP(high) cells produced a higher number of OC in culture than DC-STAMP(low) cells and the surface expression of DC-STAMP gradually declined during osteoclastogenesis. Importantly, we showed that DC-STAMP is phosphorylated on its tyrosine residues and physically interacts with SHP-1 and CD16, an SH2-domain-containing tyrosine phosphatase and an ITAM-associated protein, respectively. Taken together, these data show that DC-STAMP is a potential OCP biomarker in inflammatory arthritis. Moreover, in addition to its effect on cell fusion, DC-STAMP dynamically regulates cell signaling during osteoclastogenesis.
Ya-Hui Chiu, Kofi A Mensah, Edward M Schwarz, Yawen Ju, Masahiko Takahata, Changyong Feng, Loralee A McMahon, David G Hicks, Ben Panepento, Peter C Keng, Christopher T Ritchlin
1946 related Products with: Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).100ul100ug Lyophilized 100ul 100ul0.05 mg2 Pieces/Box96 wells (1 kit)0.1 mg1 kit(96 Wells)0.1 mg 100ul1 mg
#19294384 2009/03/18 To Up
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.To examine the role of phosphatase inhibition on anti-CD22, HB22.7-mediated lymphomacidal effects.
Robert T O'Donnell, David Pearson, Hayes C McKnight, Ya Peng Ma, Joseph M Tuscano
1742 related Products with: Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.100ul100ul0.2 mg100ug/vial100 ul100ul100ul100ug100ul
#15598811 2004/12/14 To Up
Ly49Q defines 2 pDC subsets in mice.Plasmacytoid dendritic cells (pDCs) play an important primary role for antiviral innate immunity by rapidly producing large amounts of type 1 interferon (IFN) upon viral infection. To study pDC biology, we generated a monoclonal antibody, termed 2E6, that recognizes pDCs. Molecular cloning of a cDNA encoding the 2E6 antigen revealed that it is a type II C-type lectin, Ly49Q, that consists of 247 amino acids with high homology to the natural killer (NK) receptor family Ly49, with an immunoreceptor tyrosine-based inhibitory motif in the cytoplasmic domain. Ly49Q is expressed on pDCs but not on NK cells or myeloid dendritic cells. B220+, CD11c+, CD11b- pDCs in bone marrow were divided into Ly49Q+ and Ly49Q- subsets. While both subsets produced IFN-alpha upon cytosine-phosphate-guanosine (CpG) and herpes simplex virus stimulation, Ly49Q- pDCs responded poorly to influenza virus. In addition, Ly49Q- pDCs produced inflammatory cytokines such as interleukin 6 (IL-6), IL-12, and tumor necrosis factor alpha (TNF-alpha) upon stimulation at lower levels than those produced by Ly49Q+ pDCs. In contrast to bone marrow, Ly49Q+ pDCs were only found in peripheral blood, lymph nodes, and spleen. These results indicate that Ly49Q is a specific marker for peripheral pDCs and that expression of Ly49Q defines 2 subsets of pDCs in bone marrow.
Yumiko Kamogawa-Schifter, Jun Ohkawa, Sahori Namiki, Naoko Arai, Ken-Ichi Arai, Yongjun Liu 1 G250ul10mg101002000 Units 500 G10mg20mg5 200ul50
#15501759 // To Up
Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.Protective antigen (PA) is central to the action of the lethal and edema toxins produced by Bacillus anthracis. It is the common cell-binding component, mediating the translocation of the enzymatic moieties (lethal factor [LF] and edema factor) into the cytoplasm of the host cell. Monoclonal antibodies (MAbs) against PA, able to neutralize the activities of the toxins in vitro and in vivo, were screened. Two such MAbs, named 7.5 and 48.3, were purified and further characterized. MAb 7.5 binds to domain 4 of PA and prevents the binding of PA to its cell receptor. MAb 48.3 binds to domain 2 and blocks the cleavage of PA into PA63, a step necessary for the subsequent interaction with the enzymatic moieties. The epitope recognized by this antibody is in a region involved in the oligomerization of PA63; thus, MAb 48.3 does not recognize the oligomer form. MAbs 7.5 and 48.3 neutralize the activities of anthrax toxins produced by B. anthracis in mice. Also, there is an additive effect between the two MAbs against PA and a MAb against LF, in protecting mice against a lethal challenge by the Sterne strain. This work contributes to the functional analysis of PA and offers immunotherapeutic perspectives for the treatment of anthrax disease.
Fabien Brossier, Martine LÃ©vy, Annie Landier, Pierre Lafaye, MichÃ¨le Mock
2005 related Products with: Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.1 mg1 mg1 mg100 ug1 mg100ug100 ug100ug100 ug1 mg100 ug1 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia